Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

The only solution for intractable cancer caused by mutations in the p53 gene Planning clinical trials targeting cancer patients with no available treatment due to p53 gene mutations SEOUL, South Korea, April 25, 2024 /PRNewswire/ — Hyundai Bioscience announced on April 25th that its…